A Study to Assess the Pharmacokinetics, Metabolism and Excretion Routes of ASP3652 in Man, After Administration of 14C Radio Labeled ASP3652

NCT02046798 ↗

Phase 1 Completed 6 enrolled Astellas Pharma Europe B.V.

NaSingle-groupOpen-labelBasic science

Summary

This study measures how much of the trial drug enters the body and how long it takes for the body to remove it via the feces and urine. In addition, the different breakdown products after a single oral dose of radio-active ASP3652 will be identified.

Timeline

Start: 2012-07
Primary completion: 2012-08
Completion: 2012-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ASP3652	Unknown	—	Oral

Indications

No indication recorded.